Director Lim receives 18,000 Maze (MAZE) options vesting by 2027

Rhea-AI Filing Summary

Maze Therapeutics director Jonathan E. Lim received a grant of 18,000 stock options for common stock. The options have an exercise price of $23.58 per share and bring his reported option holdings to 18,000.

The award vests and becomes fully exercisable on the earlier of the company’s 2027 annual stockholders meeting or June 8, 2027, if he continues serving the company through that date. This is a compensation-related grant rather than an open-market purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Lim Jonathan E

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	18,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 18,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 18,000 options Exercise price: $23.58 per share Total options held after grant: 18,000 options +2 more

5 metrics

Options granted 18,000 options Stock Option (Right to Buy) grant to director Lim

Exercise price $23.58 per share Exercise price of granted stock options

Total options held after grant 18,000 options Total derivative securities following transaction

Expiration date June 7, 2036 Option expiration date

Underlying shares 18,000 shares Common stock underlying granted options

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, vesting

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 23.5800"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-07T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vesting financial

"The option shall vest and be fully exercisable on the earlier of..."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lim Jonathan E

(Last) (First) (Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$23.58	06/08/2026		A		18,000		(1)	06/07/2036	Common Stock	18,000	$0	18,000	D

Explanation of Responses:

1. The option shall vest and be fully exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 8, 2027, subject to the reporting person's continued service to the issuer on the vesting date.

	/s/ Courtney Phillips, as attorney-in-fact	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Maze Therapeutics (MAZE) report for Jonathan E. Lim?

Maze Therapeutics reported that director Jonathan E. Lim received a grant of 18,000 stock options. These options give him the right to buy common shares at a fixed exercise price as part of his director compensation, not through open-market trading.

How many Maze Therapeutics (MAZE) options did Jonathan E. Lim receive and at what price?

Jonathan E. Lim received 18,000 stock options with an exercise price of $23.58 per share. This means he can later buy Maze Therapeutics common stock at $23.58, regardless of the market price at exercise, once the options vest.

When do Jonathan E. Lim’s Maze Therapeutics (MAZE) stock options vest?

The options vest and become fully exercisable on the earlier of Maze Therapeutics’ 2027 annual stockholders meeting or June 8, 2027. Vesting is conditional on Lim’s continued service to the company through that vesting date, aligning the award with ongoing board service.

When do Jonathan E. Lim’s Maze Therapeutics (MAZE) stock options expire?

The stock options granted to Jonathan E. Lim expire on June 7, 2036. After this expiration date, any unexercised options become worthless, so he must wait for vesting but exercise before that 2036 expiration to benefit from the grant.

Are Jonathan E. Lim’s Maze Therapeutics (MAZE) options an open-market purchase or compensation grant?

The 18,000 Maze Therapeutics options are a compensation-related grant, not an open-market purchase. They were awarded at a $0.00 grant price with a $23.58 exercise price, consistent with equity awards directors receive for their board service at the company.